Use and misuse of surrogate outcomes in arrhythmia trials

Circulation

Volumn 113, Issue 6, 2006, Pages 764-766

  Connolly, Stuart J ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Arrhythmia; Editorials; Trials

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER;

CARDIOMYOPATHY; CLINICAL TRIAL; DEFIBRILLATOR; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FATALITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LETHALITY; MORTALITY; PRIORITY JOURNAL; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL; SYNCOPE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; METHODOLOGY; NOTE;

ARRHYTHMIA; BIOLOGICAL MARKERS; CLINICAL TRIALS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; TREATMENT OUTCOME;

EID: 33644860326     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.600668     Document Type: Editorial

References (10)

1. Funck-Brentano C, Kroemer HK, Lee JT, Roden D. Propafenone. N Engl J Med. 1990;322:518-525.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989:321:406-412.
3. Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation. 2003;108:2596-2603.
4. Eriksson B. Ximelagatran in orthopedic surgery. Pathophysiol Haemost Thromb. 2005;34(suppl 1):10-17.
5. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A, for the SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293: 690-698.
6. Grimm W, Flores BT, Marchlinski FE. Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation. 1993;87:1880-1888.
7. Ellenbogen KA, Levine JH, Berger RD, Daubert JP, Winters SL, Greenstein E, Shalaby A, Schaechter A, Subacius H, Kadish A. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation. 2006;113:776-782.
8. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boszor S, Domanski M, Follmann D, Gent M, Roberts RS. Overview of the implantable cardioverter secondary prevention trials. Eur Heart J. 2000;21:2071-2078.
9. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165-171.
10. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Oterness MF, Adkisson WO, Canby RC, Khalighi K, Machada C, Rubenstein DS, Volosin KJ. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter defibrillators. Circulation. 2004;110:2591-2596.